SEC Form 4 · accession 0001883966-26-000003
Enveric Biosciences, Inc. · ENVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter J. Facchini
Officer — Chief Innovation Officer
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 4:22 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000890821
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 1, 2026 | A | 25,000 | $0.00 | A | 27,755 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.
- F2On October 28, 2025, the common stock of the Company began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.